Cellectis S.A. ALCLS
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Cellectis S.A. is a clinical-stage biopharmaceutical company specializing in the development of next-generation immunotherapies for cancer. With over 25 years of innovation, Cellectis leverages its proprietary TALEN® gene-editing technology to engineer chimeric antigen receptor (CAR) T-cells, creating "off-the-shelf" a…
SectorHealthcare
ExchangeXPAR
IndustryBiotechnology
CountryFrance
Employees224
TickerALCLS
Statistics
Market Cap$320.7M
Revenue (TTM)$86.4M
Net Income—
Net Margin—
EPS—
P/E-4.01
P/S3.71
P/B3.89
EV/EBITDA-3.00
ROE-76.3%
Dividend Yield—
Price$3.19
Data: Twelve Data · Revenue = mcap / P/S